January 17, 2007

Andreas Busch and Kemal Malik appointed to the Board of Management of Bayer Schering Pharma

Marc Rubin, Board member for R&D, resigns his position

Berlin/Leverkusen - The Supervisory Board of Bayer Schering Pharma AG has
appointed Prof. Dr. Andreas Busch (43) and Dr. Kemal Malik (44) to the company'
s Board of Management effective February 1, 2007. The decision was made at a
Supervisory Board meeting on Wednesday prior to the Extraordinary Stockholders'
Meeting in Berlin. Busch and Malik will also become members of the Bayer
HealthCare Executive Committee.

Prof. Dr. Marc Rubin, currently member of the Bayer Schering Pharma Board of
Management responsible for research and development and member of the Bayer
HealthCare Executive Committee will leave the company by mutual consent,
effective January 31, 2007. At this stage in the evolution of Bayer Schering
Pharma, there is an ever increasing need for the Head of Research and
Development to be present in Germany. Accordingly, Prof. Dr. Marc Rubin has
decided to resign from his position on the Board of Management, citing the
impracticality, from both a business and a family perspective, of running the
organization while based in the United States.

Rubin's present duties are to be split between the two new Board members. Busch
will head up research, while Malik will assume responsibility for development.

Prof. Dr. Andreas Busch is currently Head of Global Drug Discovery at Bayer
Schering Pharma.

Busch, born on August 26, 1963 in Pirmasens, Germany, studied pharmacy at the
Johann Wolfgang Goethe University in Frankfurt am Main. After gaining a Ph.D.
in pharmacology in 1989, he worked at several research institutes in Germany
and the United States. In 1997 Busch was appointed head of cardiovascular
research at Hoechst Marion Roussel, assuming the same position with Aventis as
of 1999. As global head of cardiovascular research at Sanofi-Aventis, Busch was
also responsible for the two research sites in Frankfurt am Main and Paris. He
joined Bayer HealthCare in 2005, where he initially served as Head of Discovery
Europe for the Pharmaceuticals Division in Wuppertal.

Before starting his career in industry, Andreas Busch was a Heisenberg Fellow
at the University of Tübingen and the Max Planck Institute in Göttingen. He is
also an Adjunct Professor of Pharmacology at the Johann Wolfgang Goethe
University in Frankfurt.

Dr. Kemal Malik is currently Head of Global Development and Chief Medical
Officer at Bayer Schering Pharma.

Malik was born on September 29, 1962 in Slough, U.K. He gained a B.Sc. in
Pharmacology at the University of London in 1984 and studied medicine at the
Charing Cross and Westminster Medical School of the University of London,
graduating as M.D. in 1987. Kemal Malik subsequently spent several years in
clinical medicine at the Northwick Park Clinical Research Centre and at
Hammersmith Hospital, London. After that Malik held various positions of
increasing responsibility in medical affairs and clinical development at
Bristol-Myers Squibb in the U.K.

Malik joined Bayer in 1995 as Head of Metabolism and Oncology Europe. He
subsequently served as Head of Global Medical Development before being
appointed Head of Global Development and Compliance.

Forward-looking statements<br/>
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in our public reports filed with the Frankfurt Stock
Exchange and with the U.S. Securities and Exchange Commission (including our
Form 20-F). The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or developments.